The Presence of Bulky Disease and/or Very High LDH Defines a High-Risk Subset of IPI 1-2 for Eligibility in Clinical Trials of Newly Diagnosed Aggressive B-Cell LymphomaMatthew J. Maurer,Arushi Khurana,Umar Farooq,Jason T. Romancik,Jonathan W. Friedberg,Izidore S. Lossos,Brad S. Kahl,Peter Martin,Dai Chihara,Andrew L. Feldman,Sergei Syrbu,David L. Jaye,Elliot Cahn,Thomas M. Habermann,Brian K. Link,James R. Cerhan,Christopher R. Flowers,Loretta J. Nastoupil,Grzegorz S. NowakowskiBLOOD（2023）引用 0|浏览0暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
